Four companies receive approval to sell generic ofloxacin

The FDA in May approved an abbreviated new drug application for four companies to manufacture and sell a generic oxfloxacin ophthalmic solution 0.3% for the treatment of bacterial eye infections, including bacterial conjunctivitis and corneal ulcers.

Related Videos
View All
Related Content

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Diagnosis and treatment: Manage dry eye with these tips

January 30th 2023

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Diagnosis and treatment: Manage dry eye with these tips

January 30th 2023

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Commercial real estate and your practice, part two with Colin Carr

May 21st 2022

Study: Retina specialists gain awareness of biosimilars

January 31st 2023

Tips, tricks, what to dos and what not to dos on how you can save money as a healthcare provider on your commercial real estate (Part 1)

May 12th 2022

Diagnosis and treatment: Manage dry eye with these tips

January 30th 2023

HuidaGene Therapeutics gains FDA clearance for multinational clinical trial of investigational new drug

January 30th 2023
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.